BD (NYSE: BDX) recently revealed the appointment of Rima Alameddine as the global president of its Peripheral Intervention division, effective from May 13. Alameddine will lead the division’s global strategies, operations, quality, and commercial efforts, reporting directly to Rick Byrd, Executive VP and President of BD Interventional.
“Rima’s over 25 years in healthcare brings vigorous leadership and exceptional execution skills,” Byrd stated in the announcement. “Her leadership paired with our innovative pipeline allows BD Peripheral Intervention to strengthen its growth trajectory and benefit patients in diverse peripheral vascular and oncology realms.”
Alameddine, part of BD since 2015, most recently served as worldwide president of BD Urology and Critical Care starting October 2021. Previously, she served as VP and general manager for C.R. Bard’s Latin American operations and was later appointed as VP and general manager for the Oncology platform within BD Peripheral Intervention.
Before joining BD, Alameddine held multiple executive roles at GE HealthCare over an 11-year period, including chief marketing officer for Latin America.
Recent BD Executive Appointments
Alameddine’s promotion coincides with a series of executive changes at BD in recent months.
In February, Dave Hickey, EVP and president of Life Science, announced plans to retire on July 1, 2024. Initially recruited by BD in 2014 as president of Diagnostic Systems, Hickey advanced to the role of president of Integrated Diagnostic Solutions in 2019, and has led the Life Sciences segment since January 2021.
Additionally, in April, BD appointed Rian Seger as president of BD Surgery. Formerly VP and general manager of the Medication Delivery Solutions business unit in BD Medical, Seger now leads the global strategy, operations, and commercial endeavors of BD Surgery, reporting to Byrd.